Clinical trials: Oxycodone
Pain
A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)
The purpose of this study is to see if changing from one pain medication like morphine or oxycodone to another pain medication, oxymorphone (OPANA®), will be helpful to patients.
- Trial name
- NCT00580294
- Testing
- Oxymorphone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Healthy
Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)
The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).
- Trial name
- NCT00955110
- Testing
- Oxymorphone ER, Oxycodone CR, Hydromorphone
- Where
- Canada
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Postoperative Pain
OxyNorm Capsules in Post-Operative Pain Study
The efficacy and safety of oxycodone capsules compared with morphine tablets in hospitalized patients with moderate to severe pain following surgery.
- Trial name
- NCT01675635
- Testing
- OxyNorm Capsules, Morphine tablet
- Volunteers
- 240 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Chronic Pain, Opioid Use
Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills
This study will examine how the use of Xtampza ER, an opioid analgesic packaged in openable microsphere-containing capsules, affects swallowing satisfaction, pain, and physical and mental health outcomes in chronic pain patients.
- Conditions
- Chronic Pain, Opioid Use, Deglutition
- Trial name
- NCT03588806
- Testing
- Xtampza ER (oxycodone)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ajay Wasan, MD, Msc
Osteoarthritis, Hip, Osteoarthritis, Knee
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back…
- Conditions
- Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
- Trial name
- NCT00361504
- Testing
- Oxycodone CR, Tapentadol (CG5503) ER
- Where
- 52 sites in United States, Canada
- Volunteers
- 1,123 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pain, Knee Osteoarthritis
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to…
- Trial name
- NCT00486811
- Testing
- Tapentadol ER (100 to 250 mg twice daily), Oxycodone CR (20 to 50 mg twice daily)
- Where
- 100 sites in Austria, Croatia and 11 more
- Volunteers
- 990 people
- Sponsor
- Grünenthal GmbH
Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant…
- Trial name
- NCT01192295
- Testing
- Oxycodone HCl controlled-release tablets
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 155 people
- Sponsor
- Purdue Pharma LP
Moderate to Severe Pain Due to Diabetic Polyneuropathy
A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy
To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone.
- Trial name
- NCT00944697
- Testing
- Oxycodone Naloxone
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused when they are crushed and snorted.
- Trial name
- NCT01775189
- Testing
- crushed ALO-02 30 mg/3.6 mg, crushed oxycodone IR 30 mg
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Pain
OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
This is an open-label, randomized, single-dose, parallel group study. The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN…
- Trial name
- NCT02880475
- Testing
- OXN PR tablet
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Pain
Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
The objective of this study is to characterize the pharmacokinetics and to evaluate the safety of single and multiple doses of Oxycodone Oral Solution in pediatric and adolescent subjects for postoperative pain.
- Trial name
- NCT01959204
- Testing
- Oxycodone
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- VistaPharm, Inc.
Physiologically Based Pharmacokinetic, Healthy Volunteers
A Study on Oral and Intranasal Forms of Oxycodone in Healthy Volunteers Using Pharmacokinetic Modeling
This is a single-dose, 2-period, 2-sequence, fasting, open label, crossover randomized design, comparing the pharmacokinetics (PK) and pharmacodynamics (PD) of intranasal and oral oxycodone solutions.
- Trial name
- NCT07223450
- Testing
- Oxycodone IN, oxycodone
- Where
- Spain
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Parc de Salut Mar
Chronic Pain
Open-Label Trial Comparing Oxycodone Medications
The investigators hypothesize that subjects will have greater pain relief when taking IR-oxycodone compared with ER-oxycodone for several reasons.
- Trial name
- OUTCOMES (NCT01162304)
- Testing
- Extended Release Oxycodone, Immediate Release Oxycodone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Rochester
Pain
Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
The purpose of this study is to determine whether oxycodone HCl and niacin are effective in the treatment of pain following bunionectomy surgery.
- Trial name
- NCT00654069
- Testing
- Acurox 5/30 mg, Acurox 7.5/30
- Volunteers
- 405 people
- Sponsor
- Acura Pharmaceuticals Inc.
Healthy Volunteers
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
To assess the bioequivalence of reformulated OXY tablets (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fed state.
- Trial name
- NCT01100320
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Moderate-severe Pain
Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain
Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of oxycodone hydrochloride with a sequestered naltrexone core in children 7-17 with moderate-severe pain.
- Trial name
- NCT02680847
- Testing
- ALO-02
- Where
- 16 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pfizer
Back Pain Lower Back Chronic
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01125917
- Testing
- Buprenorphine transdermal patch
- Where
- 84 sites in United States
- Volunteers
- 354 people
- Sponsor
- Purdue Pharma LP
Healthy Volunteers
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (10 mg) relative to the original OxyContin® (OXY) formulation (10 mg) in the fasted state.
- Trial name
- NCT01100086
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Opioid Abuse, Opioid Dependence
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Opioid drugs increase glial cell activation which may be related to the abuse liability of opioid drugs. Data supporting this hypothesis have demonstrated that glial cell attenuators decrease the positive rewarding aspect of…
- Trial name
- NCT01740414
- Testing
- MN-166 (50 mg) First
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- New York State Psychiatric Institute
Back Pain Lower Back Chronic
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal system (BTDS) 5 and oxycodone immediate-release in…
- Trial name
- NCT00313014
- Testing
- Buprenorphine, Oxycodone Immediate-Release
- Where
- 85 sites in United States
- Volunteers
- 660 people
- Sponsor
- Purdue Pharma LP